fasudil has been researched along with Parkinson Disease in 6 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil treatment significantly reduced α-Syn aggregation in vitro in a H4 cell culture model as well as in a cell-free assay." | 1.43 | Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. ( Bähr, M; Becker, S; Dambeck, V; Eckermann, K; Fonseca-Ornelas, L; Koch, JC; Lingor, P; Lopes da Fonseca, T; Outeiro, TF; Tatenhorst, L; Tönges, L; Walle, H; Zweckstetter, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, YC | 1 |
| Li, YH | 2 |
| Xiao, BG | 2 |
| Wang, J | 1 |
| Xi, JY | 2 |
| Yu, WB | 2 |
| Ostendorf, F | 1 |
| Metzdorf, J | 1 |
| Gold, R | 1 |
| Haghikia, A | 1 |
| Tönges, L | 3 |
| Lopez-Lopez, A | 1 |
| Labandeira, CM | 1 |
| Labandeira-Garcia, JL | 1 |
| Muñoz, A | 1 |
| Tatenhorst, L | 2 |
| Saal, KA | 1 |
| Koch, JC | 2 |
| Szegő, ÉM | 1 |
| Bähr, M | 2 |
| Lingor, P | 2 |
| Eckermann, K | 1 |
| Dambeck, V | 1 |
| Fonseca-Ornelas, L | 1 |
| Walle, H | 1 |
| Lopes da Fonseca, T | 1 |
| Becker, S | 1 |
| Outeiro, TF | 1 |
| Zweckstetter, M | 1 |
| Yu, JW | 1 |
| Liu, JC | 1 |
| Wang, Q | 1 |
| Song, LJ | 1 |
| Feng, L | 1 |
| Yan, YP | 1 |
| Zhang, GX | 1 |
| Ma, CG | 1 |
6 other studies available for fasudil and Parkinson Disease
| Article | Year |
|---|---|
Cellular and Molecular Mechanisms Underly the Combined Treatment of Fasudil and Bone Marrow Derived-Neuronal Stem Cells in a Parkinson's Disease Mouse Model.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Mice; Neural Stem Cells; Neurons; Parkinson Disease; Phosph | 2023 |
Propionic Acid and Fasudil as Treatment Against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cell Survival; Cells, Cul | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind | 2020 |
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Agents; Animals; Apomorphine; Corpus Stria | 2014 |
Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; alpha-Synuclein; Amides; Animals; Brain; Carrier Prot | 2016 |
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2017 |